MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?

Gastric cancer remains a disease with a dismal prognosis. Extensive efforts to find targetable disease drivers in gastric cancer were implemented to improve patient outcomes. Beyond anti-HER2 therapy, MET pathway seems to be culprit of cancer invasiveness with MET-overexpressing tumors having poorer...

Descripción completa

Detalles Bibliográficos
Autores principales: El Darsa, Haidar, El Sayed, Rola, Abdel-Rahman, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547764/
https://www.ncbi.nlm.nih.gov/pubmed/33116950
http://dx.doi.org/10.2147/JEP.S242958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547764/
https://www.ncbi.nlm.nih.gov/pubmed/33116950
http://dx.doi.org/10.2147/JEP.S242958

Ejemplares similares